Blincyto

Blincyto uses and dosage

Blincyto (Blinatumomab), is a prescription medicine used to treat CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL), including patients in first or second complete remission with minimal residual disease (≥0.1%), those with relapsed or refractory disease, and patients with Philadelphia chromosome-negative ALL during the consolidation phase of multiphase chemotherapy. Blincyto manufactured by AMGEN Pharma Ltd. In USA. Blinatumomab is administered as a continuous 24-hour intravenous infusion via a pump, typically once per treatment cycle, under the supervision of a physician. Initial monitoring is recommended during the first 1–2 days to ensure patient safety.

Blincyto side effects

The most common side effects of Blinatumomab are: Fever, Headache, tremor, chills, Infusion, Cytopenias.

Originator brand

Blincyto by Amgen Inc

Made by

AMGEN Pharma

This information is provided for reference only and is not medical advice. Always consult a qualified healthcare professional.